H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on RCUS stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Emily Bodnar has given her Hold rating due to a combination of factors influencing Arcus Biosciences’ current position. The updated ARC-20 study data for casdatifan (cas) in treating clear cell renal cell carcinoma showed consistent efficacy and safety across various cohorts, yet the overall response rate and progression-free survival outcomes, while promising, did not significantly surpass competitive benchmarks. The safety profile, including notable occurrences of Grade 3+ treatment-related adverse events, also factored into the cautious outlook.
A significant consideration was Gilead’s decision not to opt-in for the co-development or co-promotion of cas, despite their participation in an equity raise. This unexpected move by Gilead, who has historically supported Arcus’ programs, introduces uncertainty regarding future collaborative efforts and potential market traction for cas. These elements collectively contribute to a balanced view, justifying the Hold rating as investors await further developments, particularly the initiation and results of the Phase 3 PEAK-1 study.
In another report released today, Bank of America Securities also maintained a Hold rating on the stock with a $22.00 price target.